Locations
United Kingdom · London, UK · Mile End, London, UK · Kingston Vale, London SW15, UK
industry
Artificial Intelligence (AI) · Biotechnology · Life Science · Therapeutics
Size
11 - 50 employees
Stage
Series B
founded in
2021
Charm Therapeutics designs and develops a new generation of small-molecule therapeutics that target the interaction between menin and the KMT2A protein, a key driver of Acute Myeloid Leukemia (AML), using its proprietary AI-powered platform called DragonFold. The company’s lead program is a menin inhibitor optimized to maintain activity against all known clinical resistance mutations while minimizing safety and drug-interaction risks. Charm Therapeutics employs protein-ligand co-folding intelligence to inform molecular design, advancing its pipeline from preclinical stages toward the clinic.
Something looks off?
